The Efficacy and Safety of Humanized Antibody Targeting the Interleukin-4 Receptor Alpha Subunit (IL-4Rα) in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Standard Treatment: A Randomized, Double-Blind, Placebo-controlled IIT Study
Status: Recruiting
Location: See location...
Intervention Type: Other, Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Voluntarily sign the informed consent form.
Locations
Other Locations
China
Beijing Tongren Hospital, Capital Medical University
RECRUITING
Beijing
Contact Information
Primary
Luo Zhang
dr.luozhang@139.com
+86-13910830399
Time Frame
Start Date: 2024-03-18
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 120
Treatments
Experimental: Interleukin-4 receptor responders
Interleukin-4 receptor was injected subcutaneously.
Placebo_comparator: Placebo
Placebo was injected subcutaneously.
Related Therapeutic Areas
Sponsors
Leads: Beijing Tongren Hospital